T1	intervention 34 65	regional or general anaesthesia
T2	location 782 862	Argentina, Austria, China, Germany, Ireland, New Zealand, Singapore, and the USA
T3	average-age 875 884	<85 years
T4	eligibility 886 946	having potentially curative primary breast cancer resections
T5	control 1055 1074	general anaesthesia
T6	outcome-Measure 1135 1179	local or metastatic breast cancer recurrence
T7	outcome-Measure 1207 1248	incisional pain at 6 months and 12 months
T8	duration 1449 1487	Between Jan 30, 2007, and Jan 18, 2018
T9	No-of-participants 1489 1493	2132
T10	intervention-participants 1569 1573	1043
T11	control-participants 1626 1630	1065
T12	intervention-value 1833 1836	102
T13	intervention-value 1838 1841	10%
T14	outcome 1843 1854	recurrences
T15	control-value 1884 1887	111
T16	control-value 1889 1892	10%
T17	outcome 1995 2010	Incisional pain
T18	intervention-value 2027 2030	442
T19	intervention-value 2032 2035	52%
T20	intervention-participants 2040 2043	856
T21	control-value 2100 2103	456
T22	control-value 2105 2108	52%
T23	control-participants 2113 2116	872
T24	outcome 2159 2170	at 6 months
T25	intervention-value 2179 2182	239
T26	intervention-value 2184 2187	28%
T27	intervention-participants 2192 2195	854
T28	control-value 2209 2212	232
T29	control-value 2214 2217	27%
T30	control-participants 2222 2225	852
T31	outcome 2250 2262	at 12 months
T32	outcome 2333 2356	Neuropathic breast pain
T33	intervention-value 2417 2419	87
T34	intervention-value 2421 2424	10%
T35	intervention-participants 2429 2432	859
T36	control-value 2489 2491	89
T37	control-value 2493 2496	10%
T38	control-participants 2501 2504	870
T39	outcome 2547 2558	at 6 months
T40	intervention-value 2567 2569	57
T41	intervention-value 2571 2573	7%
T42	intervention-participants 2578 2581	857
T43	control-value 2595 2597	57
T44	control-value 2599 2601	7%
T45	control-participants 2606 2609	854
T46	outcome 2634 2646	at 12 months
